Financière de Tubize SA organizacji Cena/Sprzedaż
Jaka jest wartość Cena/Sprzedaż organizacji Financière de Tubize SA?
Wartość Cena/Sprzedaż organizacji Financière de Tubize SA to 1,240,271.38
Jaka jest definicja Cena/Sprzedaż?
Wskaźnik ceny do zysku (Price to sales ratio) to wskaźnik reprezentuje koszt firmy w porównaniu do kwoty jej sprzedaży.
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
Cena/Sprzedaż firm w Health Care sektor na EURONEXT w porównaniu do Financière de Tubize SA
Czym się zajmuję organizacja Financière de Tubize SA?
Financière de Tubize S.A., through its interest in UCB, operates as a biopharmaceutical company worldwide. It discovers and develops medicines and solutions in the therapeutic areas of neurology and immunology diseases. The company's principal products include Cimzia for treating ankylosing spondylitis, axial spondyloarthritis, Crohn's disease, non-radiographic axial spondyloarthritis, plaque psoriasis, psoriatic arthritis, and rheumatoid arthritis; Briviact, Vimpat, and Keppra for the treatment of epilepsy partial-onset seizures; Nayzilam, a nasal spray; and Neupro for treating Parkinson's disease and restless legs syndrome. It also offers Zyrtec and Xyzal for the treatment of allergy; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for use in treating narcolepsy with cataplexy in adult patients. The company's products in pipeline include padsevonil for drug resistant epilepsy; UCB0107 for treating progressive supranuclear palsy; UCB0599 for Parkinson's disease; UCB7858 for auto-inflammatory diseases; bimekizumab to treat psoriasis, psoriatic arthritis, hidradenitis suppurativa, and axial spondyloarthritis; rozanolixizumab to treat myasthenia gravis, immune thrombocytopenia, and chronic inflammatory demyelinating polyneuropathy; and dapirolizumab pegol for systemic lupus erythematosus. Financière de Tubize S.A. is based in Brussels, Belgium.
Firmy z cena/sprzedaż podobne do Financière de Tubize SA
- Wartość Cena/Sprzedaż organizacji Akora Resources Ltd to 233,741.00
- Wartość Cena/Sprzedaż organizacji Grand Foundry to 253,583.33
- Wartość Cena/Sprzedaż organizacji Hybrigenics Societe Anonyme to 332,390.20
- Wartość Cena/Sprzedaż organizacji GORE German Office Real Estate AG to 461,396.83
- Wartość Cena/Sprzedaż organizacji BOTS to 470,473.86
- Wartość Cena/Sprzedaż organizacji Ion to 487,937.41
- Wartość Cena/Sprzedaż organizacji Financière de Tubize SA to 1,240,271.38
- Wartość Cena/Sprzedaż organizacji Lord Global to 1,306,253.21
- Wartość Cena/Sprzedaż organizacji Europa Metals to 2,131,917.22
- Wartość Cena/Sprzedaż organizacji Aura to 2,588,682.74
- Wartość Cena/Sprzedaż organizacji Aura to 2,662,742.50
- Wartość Cena/Sprzedaż organizacji Tlou to 2,949,832.67
- Wartość Cena/Sprzedaż organizacji Tlou to 3,000,995.20